Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes.
Cancer is an evolutionary process that is driven by mutation and selection. Tumors are genetically unstable, and research has shown that this is the most efficient way for cancers to evolve. Genetic instability leads to genetic heterogeneity and dynamic change within a single individual's tumor, in turn leading to therapeutic resistance. Cancer treatment has also evolved from an empirical science of killing dividing cells to the current era of 'personalized medicine', exquisitely targeting the molecular features of individual cancers. However, current personalized medicine regards a single individual's cancer as largely uniform and static. Moreover, from a strategic perspective, current personalized medicine thinks primarily of the immediate therapy selection. Ongoing research suggests that new, nonstandard personalized treatment strategies that plan further ahead and consider intratumoral heterogeneity and the evolving nature of cancer (due to genetic instability) may lead to the next level of therapeutic benefit beyond current personalized medicine.